Fabry disease

Dominique P. Germain(Université de Versailles Saint-Quentin-en-Yvelines)

Orphanet Journal of Rare Diseases

January 1, 2010

10.1186/1750-1172-5-30

Cited by 1,173

Related Papers

Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat

|New England Journal of Medicine|2016|555

Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease

|Journal of Medical Genetics|2015|363

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document

|Orphanet Journal of Rare Diseases|2015|345

Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry

|Journal of Medical Genetics|2016|147

Use of a rare disease registry for establishing phenotypic classification of previously unassigned <i>GLA</i> variants: a consensus classification system by a multispecialty Fabry disease genotype–phenotype workgroup

|Journal of Medical Genetics|2020|66